作者: Yongping Crawford , Napoleone Ferrara , None
DOI: 10.1016/J.TIPS.2009.09.004
关键词:
摘要: Identification and characterization of VEGF as an important regulator angiogenesis, FDA approval the first anti-angiogenic drugs, has enabled significant advances in therapy cancer neovascular age-related macular degeneration. However, similar to other therapies, inherent/acquired resistance drugs may occur patients, leading disease recurrence. Recent studies several experimental models suggest that tumor non-tumor (stromal) cell types be involved reduced responsiveness treatments. The present review examines role tumor- well stromal cell-derived pathways growth refractoriness anti-VEGF therapies.